PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 2007 September; 56(9): 1322–1323.
PMCID: PMC1954973

Cathepsin B gene polymorphism Val26 is not associated with idiopathic chronic pancreatitis in European patients

Pancreatitis is thought to be a disease of autodigestion triggered by premature and intracellular activation of digestive proteases.1 We and others have shown that lysosomal cathepsin B can activate trypsinogen intracellularly2 and that a large proportion of pancreatic cathepsin B is physiologically sorted into the secretory compartment.3 Further support for a role of cathepsin B in pancreatitis came from a recent study published by Mahurkar and coworkers in Gut4 in which the authors reported that a leucine to valine mutation at position 26 of cathepsin B (L26V) is associated with tropical calcifying pancreatitis (odds ratio ~2.2) in patients from southern India. Tropical calcifying pancreatitis is also associated (in up to 50% of cases) with mutations in the SPINK1 gene5—with N34S being the most common mutation. In the study by Mahurkar et al the cathepsin B L26V mutation was, however, equally as common in SPINK1 N34S patients as in SPINK1 wild type patients, which suggests that cathepsin B is involved in an independent disease causing mechanism for pancreatitis.

As idiopathic chronic pancreatitis in Western countries and tropical calcifying pancreatitis in India share a high prevalence of SPINK1 mutations,5 we investigated whether the former is also associated with the L26V cathepsin B mutation. We studied 64 patients with idiopathic chronic pancreatitis (ICP, defined as having unequivocal morphological evidence of chronic pancreatitis on computed tomography or endoscopic retrograde cholangio‐pancreatography, or both) from northern Germany (aged 3 to 68 years; 38 male, 26 female) and 100 locally recruited healthy control subjects according to a recently reported ethics committee approved protocol.6 Patients with known risk factors for pancreatitis, such as a history of regular alcohol consumption (more than two drinks or 20 g a day), or with biliary, metabolic, or endocrine disorders, cystic fibrosis, or hereditary pancreatitis were excluded.

Genomic DNA was extracted from blood leucocytes and polymerase chain reaction amplification of exons 2 and 3 of the cathepsin B gene was undertaken using specific oligonucleotides (sense: CGA GAC GGT GCC CCT GTG TGT G; antisense: GAG GCC TTC ACT CTC CCA CTT CC). Sequencing of cathepsin B exons in ICP patients identified 31 heterozygous and 10 homozygous Val26 alleles (allele frequency 0.398), while in the control cohort we found 46 heterozygous and 25 homozygous Val26 mutations (allele frequency 0.48; table 11).). To our surprise and in contrast to the study by Mahurkar et al,4 the allele frequency of cathepsin B Val26 appeared to be even higher among controls than among ICP patients.

Table thumbnail
Table 1 Allele frequency of the Val26 mutation in German cohorts of ICP patients and controls

Being faced with a Val26 allele frequency higher in Western control subjects than in Indian pancreatitis patients, we searched the SNP Genbank of NCBI for ethnic cohorts in whom the frequency of the Val26 variant had been reported. From the reported 16 groups of diverse ethnic backgrounds, the nine largest cohorts (n >40) were selected, comprising 1198 individuals. The according frequencies for C–G mutations (C is replaced by G in Val26) at codon 26 are given in table 22.

Table thumbnail
Table 2 Allele frequencies of Val26 mutations in individual ethnic groups

Table 22 shows wide variation in frequency (0.32 to 0.547), with Val26 being the commonest allele in two of the cohorts. The mean Val26 frequency of 0.452 (n = 1198; 95% confidence interval, 0.410 to 0.494) approaches that of our German control subjects (0.48) and is not different from our pancreatitis patients.

We conclude that a high frequency of Val26 in a given cohort merely represents a polymorphic allele variation and not a susceptibility factor for idiopathic chronic pancreatitis. While this is likely to be the case in most ethnic groups it does not explain the findings of Mahurkar and coworkers,4 who found significantly fewer Val26 alleles in two Indian control cohorts. Their findings may either indicate subtle differences in the ethnic background of their patients and controls or they could be explained by a specific role for cathepsin B in tropical rather than idiopathic chronic pancreatitis. Further investigations addressing the role of cathepsin B in more common varieties of pancreatitis and in different ethnic groups are still urgently needed.

Acknowledgement

The study was funded in part by DFG GRK840 E3 and E4 and DFG L625/8.1 and /9.1.

Footnotes

Conflict of interest: None declared.

References

1. Lerch M M, Halangk W. Human pancreatitis and the role of cathepsin B. Gut 2006. 551228–1230.1230 [PMC free article] [PubMed]
2. Halangk W, Lerch M M, Brandt‐Nedelev B. et al Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000. 106773–781.781 [PMC free article] [PubMed]
3. Kukor Z, Mayerle J, Krüger B. et al Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. J Biol Chem 2002. 27721389–21396.21396 [PubMed]
4. Mahurkar S, Idris M M, Reddy D N. et al Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. Gut 2006. 551270–1275.1275 [PMC free article] [PubMed]
5. Rossi L, Pfutzer R H, Parvin S. et al SPINK1/PSTI mutations are associated with tropical pancreatitis in Bangladesh. A preliminary report. Pancreatology 2001. 1242–245.245 [PubMed]
6. Weiss F U, Simon P, Bogdanova N. et al Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005. 541456–1460.1460 [PMC free article] [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group